Stifel analyst Benjamin Burnett noted that first-in-human data for Revolution Medicines’ RMC-6291 were disclosed in a late-breaking abstract for the AACR-NCI-EORTC meeting and says the abstract describes “interesting efficacy in KRAS-experienced patients.” The firm, which adds that is “positively surprised by the strong ORR signal of 57% in NSCLC,” believes the program had “taken a back seat” to the RMC-6236 program and calls the abstract “not bad for a program most had written off.” Stifel has a Buy rating on Revolution Medicines shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines shares jump 13%, or $3.41, to $28.96
- JPMorgan biotech analysts hold an analyst/industry conference call
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
- Revolution Medicines participate in a conference call with JPMorgan
- Revolution Medicines price target raised to $47 from $37 at Stifel